ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5

The proteasome inhibitors (PIs) bortezomib and carfilzomib, which target proteasome 20S subunit beta 5 (PSMB5) in cells, are widely used in multiple myeloma (MM) treatment. In this study, we demonstrated the role of interferon-stimulated 20 kDa exonuclease-like 2 (ISG20L2) in MM PI resistance. Gain-...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yan, Gao, Yuhan, Huang, Jingcao, Yang, Zhuang, Luo, Hongmei, Wang, Fangfang, Xu, Juan, Cui, Yushan, Ding, Hong, Lin, Zhimei, Zhai, Xinyu, Qu, Ying, Zhang, Li, Liu, Ting, Ye, Lingqun, Niu, Ting, Zheng, Yuhuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675441/
https://www.ncbi.nlm.nih.gov/pubmed/36040812
http://dx.doi.org/10.1172/jci.insight.157081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675441/
https://www.ncbi.nlm.nih.gov/pubmed/36040812
http://dx.doi.org/10.1172/jci.insight.157081

Ejemplares similares